Device Trial Radar · NCT04391803
EvaLuate EndoVascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms With the Pipeline™ Flex Embolization Device With Shield TEchnology™ (ELEVATE)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
25
Actual
Start
May 6, 2022
Primary completion
Oct 20, 2025
Study completion Oct 20, 2025
Sponsor
- Lead sponsor
- Medtronic Neurovascular Clinical AffairsPublic (MDT)
- Sponsor type
- Industry
- First posted
- May 18, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the safety and effectiveness of the Pipeline™ Flex Embolization Device with Shield Technology™ in the treatment with acutely ruptured intracranial aneurysms.
Conditions
- Intracranial Aneurysm
- Ruptured Aneurysm
Interventions
Pipeline™ Flex Embolization Device with Shield Technology™Device
The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular treatment of adults with intracranial acutely ruptured aneurysms not amenable to clipping and coiling.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Complete Angiographic Occlusion Without Significant Stenosis, and no Rebleeding or Retreatment of the Target AneurysmTime frame: at 365-day
- Incidence of Neurological Death or Disabling Stroke Post-procedure.Time frame: at 365-day
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Yale New Haven Hospital
New Haven, Connecticut
Wellstar Kennestone Hospital
Marietta, Georgia
Rush University Medical Center
Chicago, Illinois
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.